Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ATOS · NASDAQ · Pharmaceutical Preparations
Atossa Therapeutics (ATOS) · oqro.io/stocks/ATOS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.60−0.155 (−8.86%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 10 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 12 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 27 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Mar 26 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 20, 2026 · largest single transaction ~$573K
Jan 20, 2026332K
DetailsOfficial recordInsider buying
Traded May 21, 2025 · filed 1 day later
The CEO of Atossa Therapeutics paid $9.9K out of pocket for Atossa Therapeutics shares. Shares held went up 423% with this purchase.
Insider buying
Traded Mar 26, 2025 · filed 2 days later
An Atossa Therapeutics director paid $7K out of pocket for Atossa Therapeutics shares. Shares held went up 3891% with this purchase.
Jan 20, 2026950K · @ $0.603
0 open-market purchases and 0 open-market sales by insiders of ATOS between Oct 13, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | None | None | None |
| Aug 7, 2026 | None | None | None |
| Jan 9, 2026 | None | None | None |
| Nov 12, 2025 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies